Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

116.78
Delayed Data
As of May 26
 +0.04 / +0.03%
Today’s Change
94.42
Today|||52-Week Range
127.64
+0.89%
Year-to-Date
Charting the Biotechs
May 26 / TheStreet.com - Paid Partner Content
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
May 23 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
May 25 / Zacks.com - Paid Partner Content
Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclero...
May 22 / TheStreet.com - Paid Partner Content
Patience Is a Virtue for Biotech Investing
May 24 / TheStreet.com - Paid Partner Content
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
May 16 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
May 24 / Zacks.com - Paid Partner Content